Pharmacokinetics of levetiracetam XR 500 mg tablets

Epilepsy Research

Volumn 84, Issue 2-3, 2009, Pages 224-231

  Rouits, Elisabeth ^a   Burton, Ingrid ^b   Guénolé, Evelyne ^c   Troenaru, Mona Mihaela ^a   Stockis, Armel ^a   Sargentini Maier, Maria Laura ^a  

^a UCB PHARMA   (Belgium)

^b SGS Life Science Services SA   (Belgium)

^c Therapharm Recherches   (France)

Author keywords

Bioavailability; Epilepsy; Extended release; Food interaction; Levetiracetam; Pharmacokinetics

Indexed keywords

ETIRACETAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINITIS; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; TABLET; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; HUMANS; MIDDLE AGED; PIRACETAM; SINGLE-BLIND METHOD; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 64149099916     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.02.001     Document Type: Article

References (26)

1. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
2. Berkovic S.F., Knowlton R.C., Leroy R.F., Schiemann J., Falter U., and Levetiracetam N01057 Study Group. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69 (2007) 1751-1760
3. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 21 (2007) 765-774
4. Briggs D.E., and French J.A. Levetiracetam safety profile and tolerability in epilepsy patients. Expert Opin. Drug Saf. 3 (2004) 415-424
5. Brodie M.J., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.J., and Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 (2007) 402-408
6. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
7. Chow S.C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies (1992), Marcel Dekker, New York
8. Ettinger A.B., Candrilli S.D., Davis K.L., and Manjunath R. Prevalence and cost impact of noncompliance with antiepileptic drugs in an elderly managed care population. Epilepsia 48 Suppl. 6 (2007) 401
9. Faught E., Duh M.S., Weiner J.R., Guérin A., and Cunnington M.C. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology 71 (2008) 1572-1578
10. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., Lu Z., and on behalf of the N159 Study Group. A double-blind randomized placebo-controlled trial of levetiracetam adjunctive therapy in children with partial seizures. Neurology 66 (2006) 1654-1660
11. Goug K., Hutchison M., Keene O., Byrom B., Ellis S., Lacey L., and McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform. J. 29 (1995) 1039-1048
12. Hauschke D., Steinijans W., and Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Clin. Pharmacol. Ther. Toxicol. 28 (1990) 72-78
13. Hollander M., and Wolfe D.A. Nonparametric Statistical Methods (1999), John Wiley & Sons, Chichester
14. Johannessen S.I., Battino D., Berry D.J., Bialer M., Kramer G., Tomson T., and Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug. Monit. 25 (2003) 347-363
15. Lehmann E.I. Nonparametrics: Statistical Methods Based on Ranks (1975), Holden-Day Inc., McGraw-Hill International Book Company, San Francisco
16. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
17. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of the fundamentals. J. Clin. Pharmacol. 42 (2002) 620-643
18. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J., and and the N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
19. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
20. Peltola, J., Coetzee, C., Jiménez, F., Litovchenko, T., Ramaratnam, S., Zaslavskiy, L., Lu, Z., Sykes, D.M., on behalf of the Levetiracetam XR N01235 Study Group, 2008. Once-Daily Extended-Release Levetiracetam as Add-On Therapy in Patients with Refractory Partial-Onset Seizures: Double Blind, Placebo-Controlled Trial. Epilepsia, October 14 [Epub ahead of print, doi: 10.1111/j.1528-1167.2008.01817.x].
21. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15 (1987) 657-680
22. Shorvon S.D., Löwenthal A., Janz D., Bielen E., and Loiseau P. Multicenter, double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
23. Smith B.P., Vandenhende F.R., DeSante K.A., Farid N.A., Welch P.A., Callaghan J.T., and Forgue S.T. Confidence interval criteria for assessment of dose proportionality. Pharm. Res. 17 (2000) 1278-1283
24. Sommerville K.W. Bioequivalence in development of antiepileptic drugs. Epilepsy Res. 68 (2006) 19-94
25. 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur. J. Clin. Pharmacol. 59 (2003) 621-630
26. Verrotti A., Salladini C., Di Marco G., Pisciella F., and Chiarelli F. Extended-release formulations in epilepsy. J. Child Neurol. 22 (2007) 419-426